A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board

An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT

“…Accordingly, the Alberta and BC Cancer Agency guidelines now recommend 6 courses of br as the preferred first-line treatment for the management of inhl and mantle cell lymphoma 42,43 . The Lymphoma Canada guidelines for the first-line treatment of follicular lymphoma also recommend br as the preferred regimen 44 . Updated results after 7 years of follow-up from the stil1 study demonstrated that br has pfs and time-to-next-treatment benefit over r-chop.…”

Orbital MALT Lymphoma after Autologous Stem Cell Transplantation for Follicular Lymphoma as Relapse of Diffuse Large B-Cell Lymphoma

“…8,9 Recently, high-dose chemotherapy and autologous stem cell transplantation have been evaluated as a first-line therapy for aggressive nonHodgkin lymphoma with poor prognostic indicators. [10][11][12] In this study, we report a patient who developed orbital MALT lymphoma after autologous peripheral blood stem cell transplantation for follicular lymphoma as the relapse of diffuse large B-cell lymphoma.…”

Updates from the 2016 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Follicular Lymphoma

“…The current standard of care in Canada for the first-line treatment of follicular lymphoma (fl) is bendamustine in combination with rituximab (br), followed by rituximab maintenance 1 . Justification for br as standard therapy is based on results of the phase iii stil-1 trial 2 , published in 2013, that demonstrated an improvement in progressionfree survival (pfs) with br compared with rituximab plus cyclophosphamide, vincristine, doxorubicin, and prednisolone (r-chop) [fl subgroup: not reached vs. 40.9 months respectively; hazard ratio (hr): 0.61; p = 0.0072].…”